For noninfectious diarrhea in adults living with HIV/AIDS who are on ART*

How Mytesi Works

Mytesi (crofelemer) is the only antidiarrheal that works by normalizing water flow in the gastrointestinal (GI) tract to provide symptomatic relief of diarrhea.

  • Mytesi works differently from other treatments for diarrhea
    • Mytesi is not an opioid and does not affect GI motility (movement through the GI tract)
  • Mytesi acts on 2 receptors inside the wall of the intestine to normalize the flow of water in the GI tract and block the high-volume water loss in diarrhea
  • Mytesi works inside the GI tract, and is not absorbed at a level that can be detected in the blood

Two chloride (Cl-) ion channels (called CFTR and CaCC) in the intestine regulate chloride and water secretion

Mytesi works by blocking the CFTR and CaCC channels in the wall of the intestine, normalizing the flow of water in the GI tract

  • *Indication

    MYTESI™ is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

    Important Safety Information about MYTESI

    MYTESI™ is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI.

    If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    Click to Read Full Prescribing Information

For product information, adverse event reports, and product complaint reports, please contact: 
Napo Pharmaceuticals     
email: napopharma@missionpharmacal.com        
phone: (844) 722-8256

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

©2016 Napo Pharmaceuticals Inc. All rights reserved.

350a-g-1

  • *Indication

    MYTESI™ is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

    Important Safety Information about MYTESI

    MYTESI™ is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI.

    If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    Click to Read Full Prescribing Information

  • *Indication

    MYTESI™ is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

    Important Safety Information about MYTESI

    MYTESI™ is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI.

    If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    Click to Read Full Prescribing Information

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

 

©2016 Napo Pharmaceuticals Inc. All rights reserved.

350a-g-1

For product information, adverse event reports, and product complaint reports, please contact: 
Napo Pharmaceuticals     
email: napopharma@missionpharmacal.com        
phone: (844) 722-8256

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

 

©2016 Napo Pharmaceuticals Inc. All rights reserved.

350a-g-1

  • *Indication

    MYTESI™ is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

    Important Safety Information about MYTESI

    MYTESI™ is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI.

    If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    Click to Read Full Prescribing Information

  • *Indication

    MYTESI™ is an anti-diarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.

    Important Safety Information about MYTESI

    MYTESI™ is not indicated for the treatment of infectious

    diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    Click to Read Full Prescribing Information